Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH006 Injection Combination Therapy vs Regorafenib for Advanced Hepatocellular Carcinoma
ChiCTR2600125457Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SH006 and regorafenib in hepatocellular carcinoma (HCC) (4 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Safety-related observation results such as adverse events, Progression-Free Survival (PFS) and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
SH006regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600125457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125457.